Literature DB >> 16133649

Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.

John T Schousboe1, Kristine E Ensrud, John A Nyman, Robert L Kane, L Joseph Melton.   

Abstract

Prevalent vertebral deformities are predictive of future clinical fractures independent of bone density. We used a Markov model with eight health states to estimate from the societal perspective the cost-effectiveness of using spine radiographs to identify postmenopausal women age 60 or older with one or more vertebral deformities and then treat them with anti-resorptive drug therapy to prevent fractures. We compared three strategies: 5 years of amino-bisphosphonate (alendronate) therapy for all, 5 years of alendronate therapy for only those with prevalent a radiographic vertebral deformity or no initial alendronate treatment. Lifetime direct medical and indirect costs, quality adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs) were tracked. For women with one or more prevalent vertebral deformities, the costs per QALY gained ranged from 5,084 dollars (for an 80 year old with a T-score of -2.4) to 61,192 dollars (for a 60 year old with a T-score of -1.0). For women without prevalent vertebral deformity, the costs per QALY gained ranged from 41,897 dollars (for a 60 year old with a T-score of -2.4) to 166,219 dollars (for an 80 year old with a T-score of -1.0). These results were modestly sensitive to reasonable changes in fracture rates, disutility, discount rates and assumptions about the accuracy of spinal radiographs for detecting vertebral deformity. Assuming a societal willingness to pay per QALY gained of 50,000 dollars, the strategy of performing spine radiographs in post-menopausal osteopenic women with T-scores at or below -1.5 and treating those with 1 or more prevalent vertebral deformities is likely to be cost-effective. However, further research on the accuracy of vertebral deformity ascertainment from routine clinical radiographs and on the efficacy of amino-bisphosphonate drugs for reducing the risk of non-vertebral fractures in osteopenic women is needed to define more precisely the subset of osteopenic post-menopausal women in whom use of spinal radiographs is most cost-effective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133649     DOI: 10.1007/s00198-005-1956-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  54 in total

1.  Prevalent vertebral deformity predicts incident hip though not distal forearm fracture: results from the European Prospective Osteoporosis Study.

Authors:  A A Ismail; W Cockerill; C Cooper; J D Finn; K Abendroth; G Parisi; D Banzer; L I Benevolenskaya; A K Bhalla; J B Armas; J B Cannata; P D Delmas; J Dequeker; G Dilsen; R Eastell; O Ershova; J A Falch; B Felsch; S Havelka; K Hoszowski; I Jajic; U Kragl; O Johnell; A Lopez Vaz; R Lorenc; G Lyritis; F Marchand; P Masaryk; C Matthis; T Miazgowski; H A Pols; G Poor; A Rapado; H H Raspe; D M Reid; W Reisinger; J Janott; C Scheidt-Nave; J Stepan; C Todd; K Weber; A D Woolf; G Ambrecht; W Gowin; D Felsenberg; M Lunt; J A Kanis; J Reeve; A J Silman; T W O'Neill
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

2.  An assessment tool for predicting fracture risk in postmenopausal women.

Authors:  D M Black; M Steinbuch; L Palermo; P Dargent-Molina; R Lindsay; M S Hoseyni; O Johnell
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

3.  The cost utility of bisphosphonate treatment in established osteoporosis.

Authors:  C P Iglesias; D J Torgerson; A Bearne; U Bose
Journal:  QJM       Date:  2002-05

4.  Mortality after osteoporotic fractures.

Authors:  O Johnell; J A Kanis; A Odén; I Sernbo; I Redlund-Johnell; C Petterson; C De Laet; B Jönsson
Journal:  Osteoporos Int       Date:  2003-10-30       Impact factor: 4.507

5.  Excess mortality after hospitalisation for vertebral fracture.

Authors:  John A Kanis; Anders Oden; Olof Johnell; Chris De Laet; Bengt Jonsson
Journal:  Osteoporos Int       Date:  2003-11-04       Impact factor: 4.507

6.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

7.  Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women.

Authors:  G Jones; C White; T Nguyen; P N Sambrook; P J Kelly; J A Eisman
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

8.  The components of excess mortality after hip fracture.

Authors:  J A Kanis; A Oden; O Johnell; C De Laet; B Jonsson; A K Oglesby
Journal:  Bone       Date:  2003-05       Impact factor: 4.398

9.  Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study.

Authors:  Cynthia L Leibson; Anna N A Tosteson; Sherine E Gabriel; Jeanine E Ransom; L Joseph Melton
Journal:  J Am Geriatr Soc       Date:  2002-10       Impact factor: 5.562

10.  Bone mineral density thresholds for pharmacological intervention to prevent fractures.

Authors:  Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger
Journal:  Arch Intern Med       Date:  2004-05-24
View more
  17 in total

1.  Diagnosis of vertebral fractures using a low-dose biplanar imaging system.

Authors:  K Briot; J Fechtenbaum; A Etcheto; S Kolta; A Feydy; C Roux
Journal:  Osteoporos Int       Date:  2015-06-06       Impact factor: 4.507

2.  Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis.

Authors:  Rachael L Fleurence; D Eldon Spackman; Christopher Hollenbeak
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy.

Authors:  J T Schousboe; D C Bauer; J A Nyman; R L Kane; L J Melton; K E Ensrud
Journal:  Osteoporos Int       Date:  2006-09-20       Impact factor: 4.507

4.  Cost-effectiveness of bone densitometry among Caucasian women and men without a prior fracture according to age and body weight.

Authors:  J T Schousboe; M Gourlay; H A Fink; B C Taylor; E S Orwoll; E Barrett-Connor; L J Melton; S R Cummings; K E Ensrud
Journal:  Osteoporos Int       Date:  2012-02-17       Impact factor: 4.507

Review 5.  Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures.

Authors:  John T Schousboe
Journal:  Curr Rheumatol Rep       Date:  2007-04       Impact factor: 4.592

6.  Prediction models of prevalent radiographic vertebral fractures among older women.

Authors:  John T Schousboe; Harold R Rosen; Tamara J Vokes; Jane A Cauley; Steven R Cummings; Michael Nevitt; Dennis M Black; Eric S Orwoll; Deborah M Kado; Kristine E Ensrud
Journal:  J Clin Densitom       Date:  2014-02-25       Impact factor: 2.617

7.  Prediction models of prevalent radiographic vertebral fractures among older men.

Authors:  John T Schousboe; Harold R Rosen; Tamara J Vokes; Jane A Cauley; Steven R Cummings; Michael C Nevitt; Dennis M Black; Eric S Orwoll; Deborah M Kado; Kristine E Ensrud
Journal:  J Clin Densitom       Date:  2013-11-27       Impact factor: 2.617

8.  Simplified criteria for selecting patients for vertebral fracture assessment.

Authors:  Sharon H Chou; Tamara J Vokes; Siu-Ling Ma; Maureen Costello; Harold R Rosen; John T Schousboe
Journal:  J Clin Densitom       Date:  2014-02-25       Impact factor: 2.617

9.  Does a history of non-vertebral fracture identify women without osteoporosis for treatment?

Authors:  Kathryn M Ryder; Steven R Cummings; Lisa Palermo; Suzanne Satterfield; Douglas C Bauer; Adrianne C Feldstein; John T Schousboe; Ann V Schwartz; Kristine Ensrud
Journal:  J Gen Intern Med       Date:  2008-05-06       Impact factor: 5.128

Review 10.  The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; Jeanene M Johnson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.